Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGc-0401 is an investigational mRNA-based vaccine developed by WestGene Biopharma for the prevention of Epstein-Barr virus (EBV)-related diseases. It is specifically designed for use in immunocompromised populations, such as patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), who are at high risk for EBV reactivation, viremia, and post-transplant lymphoproliferative disorders (PTLD). The vaccine delivers mRNA encoding EBV-specific glycoprotein antigens to host cells, which then produce these antigens to stimulate both humoral (neutralizing antibodies) and cellular (EBV-specific T-cell) immune responses. By enhancing EBV-specific immunity post-transplant, WGc-0401 aims to reduce the incidence of severe viral complications and improve clinical outcomes in transplant recipients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WGc-0401.